HER2-positive Early-stage Breast Cancer
Oncology
Prevalence
287.0 / 100K
Incidence
128.0 / 100K/yr
1 drug in development·1 company·1 clinical trial
Drug Pipeline by Phase
Phase 3(1)
| Drug | Company |
|---|---|
| Pertuzumab | Merus N.V. (MRUS) |
Frequently asked questions
How many drugs are in development for HER2-positive Early-stage Breast Cancer?
BioSniper tracks 1 drug in development for HER2-positive Early-stage Breast Cancer across 1 company.
How many clinical trials target HER2-positive Early-stage Breast Cancer?
There are 1 clinical trial targeting HER2-positive Early-stage Breast Cancer tracked by BioSniper.
What is the prevalence of HER2-positive Early-stage Breast Cancer?
The estimated prevalence of HER2-positive Early-stage Breast Cancer is approximately 287.0 per 100,000 population.
Deep-dive into HER2-positive Early-stage Breast Cancer
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis